RAB22A作为外体分泌在多发性骨髓瘤进展和复发中的预测因子

Bingjie Fan1,2, Li Wang1,2, Jishi Wang1,2

  • 1Department of Hematology, Affiliated Hospital of Guizhou Medical University, Guizhou Province Institute of Hematology, Guizhou Province Laboratory of Hematopoietic Stem Cell Transplantation Centre, Guiyang, China.

Aging
|March 2, 2024
PubMed
概括

RAB22A在多发性骨髓瘤 (MM) 中升高,并通过增加外分泌物分泌,上皮-介质细胞过渡 (EMT) 和免疫细胞透来驱动疾病的进展. 准RAB22A可能会改善MM的预后.